|Articles|March 11, 2021
- Pharmaceutical Executive-03-01-2021
- Volume 41
- Issue 3
Pharmaceutical Executive, March 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 4 years ago
The Amazon Effect: A Data-Fueled Customer Experienceover 4 years ago
Why ESG Performance Metrics Matterover 4 years ago
Pharma and Biotech’s 2020 Full-Year Viewover 4 years ago
Persevering for Patientsover 4 years ago
Biopharma’s Reputation Gets a Well-Earned Shot in the Armover 4 years ago
IP and Capitalover 4 years ago
IP and COVID-19over 4 years ago
Pharma Steps Up for Public Health Inequitiesover 4 years ago
FDA Relays Recent Achievements, Maps Plans for Progressover 4 years ago
IP and CollaborationNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma
4
Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors
5
